Progyny reported higher first-quarter revenue and profit while expanding its client base and continuing aggressive share repurchase activity.
Key Investor Takeaways
- Progyny, Inc. (NASDAQ:PGNY) posted first-quarter revenue growth and higher net income despite the loss of a previously disclosed large client.
- The company repurchased 8.8 million shares under its completed $200 million buyback program.
- PGNY reported 595 fertility and family-building clients, up from 532 a year earlier.
- Gross margin expanded to 25.3%, reflecting operational efficiencies and lower stock-based compensation expense.
- Management maintained full-year growth guidance and said early-stage sales activity for 2026 remains favorable.
Why PGNY Stock Is in Focus
Progyny, Inc. (NASDAQ:PGNY) released first-quarter 2026 results showing modest top-line growth alongside stronger profitability and continued expansion in its fertility and women’s health benefits platform.
Revenue increased 1.4% year-over-year to $328.5 million, compared with $324.0 million in the prior-year quarter.
The company noted that growth was partially offset by the previously disclosed non-renewal of a large client contract. Excluding revenue tied to that client transition agreement in the prior-year period, revenue increased 12.2%.
Fertility benefit services revenue rose 1.5% to $209.4 million, while pharmacy benefit services revenue increased 1.3% to $119.1 million.
Gross profit climbed 10% year-over-year to $83.1 million, and gross margin improved to 25.3% from 23.4%.
Net income increased to $24.2 million, or $0.29 per diluted share, versus $15.1 million, or $0.17 per diluted share, a year earlier.
Adjusted EBITDA declined slightly to $56.6 million from $57.8 million as the company continued investing in platform functionality and member experience initiatives.
“We’re pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
“Our current selling season is in its early stages and we’re off to a good start. Activity is healthy, overall pipeline and the early build of new pipeline is substantially favorable versus a year ago, and early commitments are pacing ahead of this time last year, all of which positions us well for this selling season.”
The company also highlighted continued share repurchases during the quarter.
Progyny bought back more than 5.5 million shares during the first quarter for $116.4 million, completing its previously authorized $200 million repurchase program.
Management said the board is currently evaluating a potential new repurchase authorization.
Why This Matters for Investors
The results may reinforce investor focus on Progyny’s ability to continue growing despite client concentration risks and broader economic uncertainty.
The company’s adjusted revenue growth excluding the lapsed client relationship suggests underlying demand for fertility and women’s health benefits remains strong.
For investors, client expansion and covered lives growth may be particularly important because they support Progyny’s long-term recurring revenue model tied to employer-sponsored healthcare benefits.
Margin expansion could also improve sentiment around operational scalability, especially as the company continues investing in platform enhancements while maintaining profitability.
The aggressive share repurchase activity may additionally signal management confidence in the company’s cash generation and balance sheet position.
At the same time, investors may continue monitoring utilization trends, employer spending patterns, and the potential impact of macroeconomic conditions on benefit adoption and healthcare usage.
What to Watch Next
Investors will likely monitor:
- Progress during Progyny’s 2026 client selling season
- Potential announcement of a new share repurchase program
- Growth in covered lives and client additions
- Member utilization trends across fertility and pharmacy services
- Margin performance as platform investments continue
- Execution against full-year revenue and EBITDA guidance